Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination

Kahn, RM; Ragupathi, G; Zhou, QC; Iasonos, A; Kravetz, S; Hensley, ML; Konner, JA; Makker, V; Tew, WP; Aghajanian, C; Sabbatini, PJ; O'Cearbhaill, RE

O'Cearbhaill, RE (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10065 USA.;O'Cearbhaill, RE (通讯作者)，Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA.;O'Cearbhaill, RE (通讯作者)，Natl Univ Ireland, Galway, Ireland.

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023; 72 (1): 183

Abstract

Background To characterize the safety, immunogenicity, and outcomes of patients with high-grade serous ovarian cancer (HGSOC) in second or greater rem......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索